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Abstract
Objective
Cross-sectional studies have shown that spinal cord volume (SCV) loss is related to disease
severity in multiple sclerosis (MS). However, long-term data are lacking. Our aim was to
evaluate SCV loss as a biomarker of disease progression in comparison to other MRI meas-
urements in a large cohort of patients with relapse-onset MS with 6-year follow-up.
Methods
The upper cervical SCV, the total brain volume, and the brain T2 lesion volume were measured
annually in 231 patients with MS (180 relapsing-remitting [RRMS] and 51 secondary pro-
gressive [SPMS]) over 6 years on 3-dimensional, T1-weighted, magnetization-prepared rapid-
acquisition gradient echo images. Expanded Disability Status Scale (EDSS) score and relapses
were recorded at every follow-up.
Results
Patients with SPMS had lower baseline SCV (p < 0.01) but no accelerated SCV loss compared
to those with RRMS. Clinical relapses were found to predict SCV loss over time (p < 0.05) in
RRMS. Furthermore, SCV loss, but not total brain volume and T2 lesion volume, was a strong
predictor of EDSS score worsening over time (p < 0.05). The mean annual rate of SCV loss was
the strongest MRI predictor for the mean annual EDSS score change of both RRMS and SPMS
separately, while correlating stronger in SPMS. Every 1% increase of the annual SCV loss rate
was associated with an extra 28% risk increase of disease progression in the following year in
both groups.
Conclusion
SCV loss over time relates to the number of clinical relapses in RRMS, but overall does not
diﬀer between RRMS and SPMS. SCV proved to be a strong predictor of physical disability and
disease progression, indicating that SCV may be a suitable marker for monitoring disease
activity and severity.
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Multiple sclerosis (MS) is an inﬂammatory disease of the
brain and the spinal cord (SC) that leads to demyelination
and neurodegeneration. Atrophy is considered to be the
consequence of neurodegeneration in MS and can be mea-
sured in vivo using MRI as a reduction of central nervous
tissue volume.1–5
SC abnormalities have been observed in up to 83% of patients
with MS, with 60% occurring in the cervical region.6–8 SC
lesions are of diagnostic as well as prognostic importance in
MS.9 However, previous studies were inconsistent regarding
the correlation between lesional SC abnormalities and MS-
related disability.1,6,10 In contrast, SC volume (SCV) or cross-
sectional area measurements have indicated a stronger and
more consistent relationship to disability in MS.4,8,10–16 In-
deed, SCV loss has been shown to be more extensive in
progressive forms of the disease.12,16,17 It mainly reﬂects
a diﬀuse process, which seems at best weakly related to focal
brain and SC MS lesions.1,18
Despite the interest raised by cross-sectional and short-term
follow-up volumetric SC studies, there is a lack of larger-scale,
longer-term longitudinal studies on SCV loss in MS. This is
mainly because the SC is infrequently included in imaging
protocols because of cost, time restrictions, and technical
diﬃculties in acquiring high-quality MRIs and in quantifying
SC metrics in a reliable and time-eﬃcient way.19,20 As a result,
there is a knowledge gap on the dynamic changes of SC
measures and their association with the patient’s clinical pic-
ture over time.
We hypothesized that SCV loss could be strongly associated
with clinical changes over time, contributing stronger to dis-
ease progression than brain MRI measurements. Our aim for
this study was to evaluate SCV loss in a large cohort of
patients with relapsing-onset MS, who have been followed
over a period of 6 years with annual clinical and MRI
examinations. Our goal was to evaluate SCV loss as a feasible
biomarker in MS in comparison to brain MRI metrics and
assess potential between-group diﬀerences in a fast, clinically
easy, applicable fashion using high-resolution brain and not
SC scans.
Methods
Study design and participants
Clinical andMRI data of patients with relapsing-remitting MS
(RRMS) and secondary progressive MS (SPMS) in an
ongoing large-scale cohort study7 (240 patients with relapse-
onset MS in total) at a single center (MS Center, University
Hospital, Basel) were analyzed. Patients were followed over
a maximum of 6 years (7 annual time points). The diagnosis
of MS was made in accordance with international panel
established criteria.21 The local ethics committee approved
the study.
Procedures
All patients underwent a standardized neurologic examination
including the Expanded Disability Status Scale (EDSS; neu-
rostatus.org) by trained and certiﬁed examiners and Timed
25-Foot Walk (T25-FW) test annually. Deﬁnite clinical dis-
ease progression was deﬁned according to the following
conventions: (1a) an increase of 1 point in the EDSS if the
baseline EDSS score was ≤5.5 or (1b) an increase of 0.5 point
in the EDSS if the baseline EDSS score was >5.5, and (2) no
relapse in the last 12 months. The number of relapses during
the 12 months prior to every follow-up was noted with every
clinical evaluation, as well as their sum from baseline to each
follow-up.
All MRI scans were performed on the same 1.5T Magnetom
Avanto MR scanner (Siemens Medical Solutions, Erlangen,
Germany). Morphologic analyses were performed on high-
resolution, 3-dimensional, T1-weighted magnetization-prepared
rapid-acquisition gradient echo brain MRI scans acquired in
sagittal orientation (repetition time/inversion time/echo time =
2,080/1,100/3.0 milliseconds; α = 15°, 160 slices, resolution:
0.98 × 0.98 × 1 mm3), covering the upper cervical SC.
SCV analysis was performed using an established semi-
automatic software (CORDIAL), which allows a fast and re-
liable segmentation and volumetry of the SC with minimal
user interaction.22,23 The segmentation was performed over
a 35-mm-long SC segment, starting 27 mm below the cisterna
pontis, which corresponds approximately to the SCV between
the foramen magnum and the C2-3 intervertebral disk (ﬁgure
e-1, links.lww.com/WNL/A588). Segmentations were visu-
ally inspected for quality and excluded from further statistical
analysis in case of segmentation errors.
Total brain volume (TBV) was computed for each patient
from the T1-weighted images with the fully automated tool
“Structural Image Evaluation, using Normalization, of Atro-
phy” for cross-sectional studies (SIENAX version 2.6).24 The
SIENAX volume-correction factor was used for normalizing
the TBV regarding variations of head size. All analyses were
performed on these corrected volumes.
Glossary
EDSS = Expanded Disability Status Scale; LMER = linear mixed-eﬀects regression; MLR = multiple linear regression; MS =
multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SC = spinal cord; SCV = spinal cord volume; SPMS =
secondary progressive multiple sclerosis; T2LV = T2 lesion volume; T25-FW = Timed 25-Foot Walk; TBV = total brain
volume.
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All brain white matter lesions (T2LV) were segmented by
trained expert observers according to the standard operating
procedures used at the local institution for the analysis of
clinical phase II and phase III trials as described before.25
Statistical analysis
The mean annual SCV loss rate, the mean annual TBV loss
rate, and the mean rate of annual T2LV increase over 6 years
were determined for every patient as the average of the annu-
alized changes between all available time points. To approxi-
mate a normal distribution, logarithmic (EDSS) and inverse
transformations (T25-FW) were performed. The annual EDSS
and annual T25-FW changes were calculated based on the
transformed scores. See appendix e-1 (links.lww.com/WNL/
A587) (including ﬁgure e-2, links.lww.com/WNL/A588)
for exact calculation formulas of mean annual rates and
changes.
Comparisons of baseline demographic factors, clinical meas-
urements, and number of follow-ups between subtypes were
made using the Welch and Pearson χ2 test with Yates conti-
nuity correction. Between-group diﬀerences regarding base-
line MRI measures and annual rates were performed using
analyses of covariance, while correcting for age, sex, and dis-
ease duration.
Hierarchical multiple linear regression (MLR) analyses were
performed to investigate the associations between annual
rates of MRI metrics and annual changes of clinical scores, in
a backward stepwise fashion. Independent variables were
entered blockwise keeping the following sequence: ﬁrst de-
mographics and clinical factors, then SCV, and ﬁnally brain
metrics. Baseline MRI and clinical measures were always en-
tered into the model as correction factors to the respective
annual rates, irrespective of whether they reached levels of
statistical signiﬁcance. All other independent variables that did
not reach levels of statistical signiﬁcance were not included in
the ﬁnal model.
Linear mixed-eﬀects regression (LMER) analyses were
deployed to explore the longitudinal correlations between
clinical andMRImeasures in a forward stepwise fashion, using
a “random intercept” and a “random slope” to allow for
within-subject and between-subject variance. Each factor was
tested both for its contribution to the ﬁt’s intercept as well as
to the ﬁt’s slope. The ﬁt’s intercept corresponds to the average
of the dependent variable, whereas the ﬁt’s slope to the change
of the dependent variable over time. Again, independent
variables were entered blockwise in the above-mentioned
sequence (see MLR). All independent variables without sta-
tistical signiﬁcance were excluded from the ﬁnal model.
To evaluate the prediction capabilities of MRI on disease
progression and time to disease progression, a Cox analysis in
a backward stepwise fashion was performed. In patients
showing disease progression, the annual rates were recalcu-
lated for the time period between baseline and time of
progression. A 10-fold cross-validation was performed, and
the corrected concordance probability index (C index) was
assessed. The contribution of each factor in the ﬁnal model
was assessed using the proportion of χ2.
All statistical analyses were performed using R version 3.2.3
(r-project.org/).
Data availability
Raw data were fully generated at the University Hospital
Basel. They were not acquired as part of a clinical trial. De-
rived data, e.g., MRI metrics (SCV, whole brain volume, etc.),
supporting the ﬁndings of this study are available from the
corresponding author (K.P.) upon reasonable request. The
data are not publicly available because of ethical restrictions.
Results
Of 1,180 available MRI datasets of 240 relapse-onset patients,
95 datasets (8%; including the complete MRI series of 9
patients) were excluded from further analysis because of
segmentation errors or image artifacts. This resulted in anal-
ysis of a total of 231 patients with MS (180 RRMS and 51
SPMS), who were followed on average over 5.1 ± 1.99 years
(ﬁgure e-3, links.lww.com/WNL/A588). Demographics and
basic clinical characteristics are described in table 1. Corrected
baseline MRI metrics, annual rates, and between-group
comparisons are shown in table 2.
SCV changes
In a ﬁrst series of statistical analyses, SCV and its change over
time was evaluated regarding demographic, clinical, and brain
MRI metrics using LMER. The analyses revealed that men
had larger average volumes than women (men: B = 289, p <
0.001), and a signiﬁcantly faster SCV loss over time (men: B =
−6.24, p < 0.01). Age (B = 3.36, p < 0.01) and disease duration
(B = −7.94, p < 0.001) correlated with the average SCV but
not with the SCV loss over time. Moreover, TBV (B = 6 ×
10−4, p < 0.001) and T2LV (B = 2 × 10−3, p < 0.05) correlated
with the average SCV but not with the SCV loss over time.
SPMS on average had lower SC volumes (SPMS: B = −175,
p < 0.01) than RRMS but not an accelerated SCV loss over
time. Overall, the full model accounted for 98.7% of SCV
variance, while the ﬁxed eﬀects alone accounted for 32.7%.
The sum of clinical relapses in patients with RRMS was as-
sociated with SCV loss over time (B = −1.06, p < 0.05) but not
with the average SCV. Disease duration (B = −9.58, p < 0.001)
was associated with the average SCV but not with the SCV
loss over time. Age did not correlate with the SCV. The ﬁnal
model accounted for 98.7% of SCV variance, while the ﬁxed
eﬀects alone accounted for 22.3% of the SCV variance.
SCV changes and disability
In a second step, we were interested in whether measures of
disability (EDSS and T25-FW) are associated with SCV and
brain MRI metrics and their changes over time.
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Expanded disability status scale
In the LMER analyses, SCV was inversely associated with
the average EDSS score (B = −4 × 10−4, p < 0.001) and the
EDSS worsening over time (B = 2.1 × 10−5, p < 0.05). TBV
and T2LV were also correlated with the average EDSS
score (B = −2.2 × 10−7, p < 0.05; B = 8.8 × 10−6, p < 0.001,
respectively) but not with the EDSS worsening over time.
Finally, sex (men: B = 0.13, p < 0.05), age (B = 5.6 × 10−3,
p < 0.001), disease duration (B = 2.8 × 10−3, p < 0.01), and
disease subtype (SPMS: B = 0.35, p < 0.001) correlated
with the average EDSS score, but not with the EDSS
worsening over time. The ﬁnal model accounted for 87.7%
of EDSS variance, while the ﬁxed eﬀects alone accounted
for 42.6%.
Separate MLR analyses were performed to speciﬁcally in-
vestigate the extent of correlation between EDSS score and
SCV in each disease type. In RRMS, the annual SC rate was
the only predictive MRI factor, while age and baseline
EDSS score contributed signiﬁcantly. The ﬁnal model
demonstrated a weak prediction of the annual EDSS
change variance, with an adjusted R2 of 19.2%. Similar to
RRMS, the annual SC rate was the most important pre-
dicting factor for the annual EDSS change in SPMS, while
again age and baseline EDSS score also contributed
signiﬁcantly. The ﬁnal model demonstrated, however,
a moderate prediction of the annual change in EDSS, with
an adjusted R2 of 53.8%. The models are described in detail
in table 3.
Timed 25-foot walk test
In the LMER analyses, SCV as well as TBV were inversely
associated with the average T25-FW test score (B = 3.7 ×
10−5, p < 0.001; B = 6.8 × 10−8, p < 0.01, respectively) but not
with its worsening over time. T2LV correlated with both, the
average T25-FW test score (B = −1.4 × 10−6, p < 0.01) and its
worsening over time (B = −2.2 × 10−7, p < 0.05). Age (B = −1
× 10−3, p < 0.001), disease duration (B = −6.2 × 10−4, p <
0.001), and disease subtype (SPMS: B = −5.7 × 10−2, p <
0.001), but not sex, correlated with the average T25-FW test
score. Only sex (men: B = − 2.9 × 10−3, p < 0.01) and disease
type (SPMS: B = −4.5 × 10−3, p < 0.05) correlated with the
T25-FW worsening over time. The ﬁnal model accounted for
94.2%, while the ﬁxed eﬀects alone accounted for 40% of the
T25-FW variance.
Separate MLR analyses were performed to speciﬁcally in-
vestigate the extent of correlation between the T25-FW
and SCV in each disease type. In the RRMS group, the
annual SC rate was the most important predicting factor,
Table 1 Demographics and basic clinical characteristics of patients with multiple sclerosis
Characteristics Overall RRMS SPMS p Value
No. of patients 231 180 51
Baseline age, y <0.001
Mean ± SD 44.7 ± 11.2 41.5 ± 10.1 55.4 ± 7.6
Range 19–67 19–65 38–67
Sex, F/M 160/71 133/47 27/24 <0.01
Baseline disease duration, y <0.001
Mean ± SD 13.1 ± 9.2 11.4 ± 8.4 19.1 ± 9.7
Range 0–47 0–40 1–47
Baseline EDSS score <0.001
Median 3.0 2.5 4.5
Range 0–7.5 0–7.5 1.5–7.5
Baseline T25-FW z score <0.001
Mean ± SD 0 ± 1 0.26 ± 0.86 −0.98 ± 0.90
Range −2.69 to 3.90 −2.69 to 3.90 −2.67 to 1.02
No. of follow-ups 0.38
Mean ± SD 5.10 ± 1.99 5.16 ± 1.99 4.88 ± 2.00
Range 1–7 1–7 1–7
Abbreviations: EDSS = Expanded Disability Status Scale; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressivemultiple sclerosis; T25-
FW = Timed 25-Foot Walk.
Between-group comparisons were performed using the Welch 2-sample t test and Pearson χ2 test with Yates continuity correction where appropriate.
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while baseline TBV also contributed signiﬁcantly. The ﬁnal
model demonstrated a weak prediction of the annual T25-
FW change variance, with an adjusted R2 of 13.9%. Re-
garding the annual T25-FW test changes in patients with
SPMS, the annual SC rate was the most important pre-
dicting factor, while baseline SCV also contributed signif-
icantly. The ﬁnal model demonstrated a moderate
prediction of the annual change in the T25-FW, with an
adjusted R2 of 49.9%. The models are described in detail in
table 3.
Prediction of disease progression
Last, the predictive capabilities of MRI metrics on disease
progression and time to disease progression were evalu-
ated. A Cox analysis showed that disease type, baseline
EDSS score, annual rate of SCV loss, and baseline TBV
were signiﬁcant predictors of disease progression. The
annual rate of SCV loss explained 34% of the ﬁnal model’s
χ2 and was the strongest MRI measure. Its hazard ratio was
0.72 (95% conﬁdence interval: 0.61–0.84, p < 0.001). Every
1% increase of the annual rate of SCV loss was associated
with an extra 28% risk increase to develop disease pro-
gression in the following year. The C index resulting from
a 10-fold cross-validation of the cohort was 70%, showing
a moderate predictive power of the model. Details are
displayed in table 4.
Discussion
This study is the ﬁrst longitudinal longer-term analysis of SCV
loss in MS investigating the upper cervical SCV in a large
cohort of patients with relapse-onset MS for up to 6 years of
follow-up. The temporal proﬁle of SC tissue loss is illustrated
with its association to clinical changes and its potential to
monitor the clinical course of the disease. For that purpose,
we deployed a fast, clinically easy applicable pipeline using
high-resolution brain scans.
The SC segmentation was performed in a mainly automatic
fashion with minimal user interaction, thus avoiding bias
from manual segmentations or manual corrections. Our ap-
proach using the upper cervical SCV instead of the upper SC
area is thought to be less susceptible to possible bias from
focal atrophy due to lesions and possesses high test-retest
reliability.22
Table 2 Adjusted MRI measures of patients with multiple sclerosis
MRI measure Overall RRMS SPMS p Value
Baseline SCV, mm3 <0.001
Mean ± SD 2,380 ± 167 2,416 ± 148 2,253 ± 170
Range 1,883–2,724 2,121–2,724 1,883–2,499
Annual SCV rate, %/y 0.24
Mean ± SD −0.43 ± 0.20 −0.38 ± 0.17 −0.62 ± 0.17
Range −0.95 to 0.04 −0.73 to 0.04 −0.95 to (−0.31)
Baseline TBV, cm3 <0.001
Mean ± SD 1,489 ± 52 1,498 ± 46 1,433 ± 40
Range 1,340–1,595 1,355–1,595 1,340–1,543
Annual TBV rate, %/y 0.41
Mean ± SD −0.43 ± 0.12 −0.41 ± 0.11 −0.50 ± 0.13
Range −0.75 to −0.17 −0.69 to −0.17 −0.75 to 0.17
Baseline T2LV, mm3 0.18
Mean ± SD 6,287 ± 1,720 5,959 ± 1,515 7,437 ± 1,910
Range 2,647–12,340 2,647–10,250 7,437–12,340
Annual T2LV rate, %/y <0.05
Mean ± SD 3.48 ± 2.53 4.34 ± 1.95 0.41 ± 1.91
Range −4.86 to 8.07 −2.90 to 8.07 −4.86 to 4.61
Abbreviations: RRMS = relapsing-remitting multiple sclerosis; SCV = spinal cord volume; SPMS = secondary progressive multiple sclerosis; T2LV = brain T2
lesion volume; TBV = total brain volume.
Baseline SCV, TBV, and T2LV were adjusted for age, disease duration, and sex. Annual SCV rate, annual TBV rate, and annual T2LV rate were adjusted for age,
disease duration, sex, and baseline SCV/TBV/T2LV, respectively. Adjusted values and significance of difference between RRMS and SPMS were obtained
through analysis of covariance.
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Table 3 Multivariate analysis of clinical measures by disease type
Group Final model Variable β p Value DR2
RRMS Annual EDSS change ; age + baseline EDSS +
baseline SCV + annual SCV rate; adjusted R2 = 19.19%;
p < 0.001
Age 0.25 <0.001 17.38%, p < 0.001
Sex — NS
Disease duration — NS
Baseline EDSS −0.51 <0.001
Baseline SCV −0.10 NS
Annual SCV rate −0.16 <0.05 1.81%, p < 0.05
Baseline TBV — NS —
Annual TBV rate — NS —
Baseline T2LV — NS —
Annual T2LV rate — NS —
Annual T25-FW change; baseline T25-FW + baseline
SCV + annual SCV rate + baseline TBV; adjusted R2 =
13.87%; p < 0.001
Age — NS 0.33%, p = 0.23
Sex — NS
Disease duration — NS
Baseline T25-FW −0.08 NS
Baseline SCV 0.07 NS
Annual SCV rate 0.35 <0.001 11.51%, p < 0.001
Baseline TBV 0.18 <0.05 2.03%, p < 0.05
Annual TBV rate — NS —
Baseline T2LV — NS —
Annual T2LV rate — NS —
SPMS Annual EDSS change ; age + baseline EDSS +
baseline SCV + annual SCV rate; adjusted R2 = 53.83%;
p < 0.001
Age −0.27 <0.05 18.25%, p < 0.001
Sex — NS
Disease duration — NS
Baseline EDSS −0.23 <0.05
Baseline SCV 0.03 NS
Annual SCV rate −0.60 <0.001 35.58%, p < 0.001
Baseline TBV — — —
Annual TBV rate — — —
Baseline T2LV — — —
Annual T2LV rate — — —
Annual T25-FW change; baseline T25-FW + baseline
SCV + annual SCV rate; adjusted R2 = 49.89%; p <
0.001
Age — NS 8.38%, p < 0.01
Sex — NS
Disease duration — NS
Baseline T25-FW 0.06 NS
Continued
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In line with previous cross-sectional studies,4,5,10–17 patients
with SPMS had lower SCV compared to patients with RRMS.
However, there was no evidence of accelerated SCV loss over
time in SPMS compared with RRMS. The observed between-
group diﬀerences in cross-sectional settings can be explained
by longer disease duration and older age of the patients with
SPMS (ﬁgure 1), arguing against a theoretical preferential
SCV loss in this group as suggested by previous smaller-scale
and shorter-duration studies.4,5,10–17 Similar ﬁndings were
present regarding TBV loss when compared between groups
in the present cohort. This is in line with a large study by De
Stefano et al.3 showing that there is no diﬀerence in the rate of
brain volume loss in earlier vs more advanced MS phenotypes
on a group level. Overall, these results indicate that the rate of
tissue loss in the CNS is in general comparable in relapse-
onset MS phenotypes.
In terms of T2LV, patients with RRMS showed faster accu-
mulation of T2LV, reﬂecting the inﬂammatory activity dom-
inating in this phase of the disease. However, SCV loss over
time seemed to be largely independent of change in TBV and
T2LV.
As expected, men had larger SCV at baseline; however, they
exhibited more pronounced SCV loss over time, which is in
line with the clinical observation that male sex is an indicator
Table 3 Multivariate analysis of clinical measures by disease type (continued)
Group Final model Variable β p Value DR2
Baseline SCV −0.26 <0.05
Annual SCV rate 0.65 <0.001 41.51%, p < 0.001
Baseline TBV — NS —
Annual TBV rate — NS —
Baseline T2LV — NS —
Annual T2LV rate — NS —
Abbreviations: β = standardized regression coefficients; DR2 = adjusted R2 difference; EDSS = Expanded Disability Status Scale; NS = not significant; RRMS =
relapsing-remitting multiple sclerosis; SCV = spinal cord volume; SPMS = secondary progressive multiple sclerosis; T2LV = brain T2 lesion volume; T25-FW =
Timed 25-Foot Walk; TBV = total brain volume.
Table 4 Cox analysis of disease progression
Final model Variable HR (95% CI)
Proportion
of χ2, % p Value
(Disease progression, time to disease progression)∼ disease type +
baseline EDSS + baseline SCV + annual SCV rate + baseline TBV
Age — — NS
Sex — — NS
Disease duration — — NS
Disease type (SPMS) 4.62 (2.46–8.67) 43.9 <0.001
Baseline EDSS 0.29 (0.15–0.58) 24.3 <0.001
Baseline SCV 1.0008 (1.0–1.002) 6.7 NS
Annual SCV rate 0.72 (0.61–0.84) 34 <0.001
Baseline TBV 1.0000
(1.0000–1.0000)
18 <0.01
Annual TBV rate — — NS
Baseline T2LV — — NS
Annual T2LV — — NS
Abbreviations: CI = confidence interval; C index = 10-fold cross-validation corrected concordance probability index; EDSS = Expanded Disability Status Scale;
HR = hazard ratio; NS = not significant; SCV = spinal cord volume; SPMS = secondary progressivemultiple sclerosis; T2LV = brain T2 lesion volume; TBV = total
brain volume.
Concordance = 0.717 (SE = 0.04); Wald test = 51.53, p < 0.001; score (log-rank) test = 54.16, p < 0.001; total χ2 = 51.54, p < 0.001; C index = 0.70.
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of poorer prognosis.26 Yet, our statistical analyses predicting
the EDSS and disease progression could not conﬁrm a faster
clinical worsening of male patients compared to females. This
may be explained by the follow-up span, whichmight not have
been long enough. Neither age nor disease duration seemed
to have an eﬀect on SCV loss over time, suggesting a relatively
steady SC tissue loss in both patient groups.
In RRMS, an increased cumulative number of clinical
relapses was associated with faster SCV loss over time. One
may speculate that with every new clinical relapse in a pa-
tient with RRMS, some degenerative cascade is activated
accelerating SCV loss, an eﬀect that seems to persist way
beyond the initial acute inﬂammatory phase of the relapse.
The data further suggest that the accumulation of clinical
relapses shapes—at least partially—a patient’s proﬁle in
terms of SCV loss. The data also imply that the reduction of
clinical relapses, which constitutes a fundamental thera-
peutic strategy of RRMS, should beneﬁcially aﬀect this
process.27 In the LMER, SCV proved to be the only MRI
metric to strongly explain the clinical progression over time
as measured by speed of EDSS worsening for the whole
cohort. TBV and T2LV were associated with the average
patient’s disability but did not independently relate to EDSS
worsening over time, when added to a statistical model that
included SCV. Regarding the T25-FW test, SCV and TBV
correlated with the patient’s walking speed, although they
failed to correlate with its worsening over time. Instead, the
T2LV was a predictor of these changes, probably driven by
the RRMS group.
Figure 1 SCV and its change over time separated by disease type: patients with RRMS (red) and SPMS (turquoise)
(A) The fine lines represent the rawmeasurements of SCV for each patient over 6 years of follow-up, while the thicker blue lines depict the respective “trends”
of SCV loss in the 2 disease types. Of note, despite a significant difference of SCV at baseline (B), the annual SCV rate did not differ significantly betweendisease
types, after adjusting for age, sex, and disease duration (C). The error bars (whiskers) represent themean ± SD. RRMS = relapsing-remittingmultiple sclerosis;
SCV = spinal cord volume; SPMS = secondary progressive multiple sclerosis.
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Regardless of a similar SCV loss pace in both patient groups,
association of the annual rate of SCV loss with clinical
scores was remarkably higher for patients with SPMS than
for the RRMS group in all analyses. This shows that
despite the assumption of the same underlying causal
pathomechanisms,27,28 the clinical eﬀect in SPMS is more
pronounced. This can be explained by older age and accu-
mulation of damage over time in patients with SPMS,
entailing chronic immune activation, increased oxidative
stress–related damage, loss of trophic support, and exhaustion
of repair and compensatory mechanisms.28,29 This allows
axonal and myelin damage to be “translated” in a much more
straightforward way into clinical deﬁcits once the threshold of
neuronal injury and/or repair has been exceeded. However, it
is possible to hypothesize that patients with RRMS still have
suﬃcient reserves of cortical adaptation, remyelination, axo-
nal repair, and neuroprotection, which allow them on one
hand to maintain or reestablish the functionality of neuronal
tissue and on the other hand “mask” the produced axonal loss
through neuroplasticity occurring at higher cortical
centers.1,21,22 Considering that, in future works, additional
measures of neuroprotective mechanisms such as quantitative
MRI measurements (e.g., magnetization transfer imaging,
diﬀusion tensor imaging, and proton magnetic resonance
spectroscopy) may shed light into this interesting aspect of
the disease.28,30,31 The annual SCV loss rate was to a great
extent the only MRI factor in predicting clinical worsening,
while the annual TBV and T2LV did not signiﬁcantly con-
tribute. Predicting disease progression using a Cox analysis, it
was shown that the annual rate of SCV loss was the strongest
MRI measure, and a 1% rate increase was associated with
a 28% risk increase to develop disease progression in the
following year. Furthermore, patients with SPMS were shown
to be more susceptible to disease progression. This also adds
to evidence that SCV could possibly be a better disease
marker compared to brain volume loss and lesion load in the
brain.
This study has a number of limitations. We aimed to analyze
follow-up data of a group of patients with MS in a retrospec-
tive manner. Some patients were lost to follow-up during the
study, leading to incomplete datasets and potential bias. While
the group of patients with SPMS was smaller than the RRMS
group, the 2 groups were followed up for a similar amount of
time. The latter at least does not support a preferential loss of
patients with progression. Furthermore, the lack of a repre-
sentative control group of healthy subjects made it impossible
to assess MS-related SC volume loss as compared to SCV
decline due to normal aging. However, it is likely that the
observed SCV loss is mainly a disease-related eﬀect because in
the normal population, the degree of SCV loss seems to be
smaller.32 Unfortunately, no study has so far assessed the
eﬀect of age on SCV loss in healthy controls longitudinally. In
this study, the potential eﬀect of disease-modifying drugs on
inﬂammation, and ultimately on SCV variation, was not in-
cluded in our analysis. In our cohort, 68% of patients were
treated with disease-modifying drugs at baseline including
primarily ﬁrst-line injectables (63%). While injectables also
show an eﬀect on brain atrophy, we believe that this eﬀect is
rather negligible.33 Finally, since the study had no T2-
weighted sequence covering the area of volume measurement
over all time points analyzed here, the impact of SC lesions
was not assessed.
In conclusion, this study indicates that measurement of SCV
loss represents a reliable imaging marker for monitoring dis-
ease activity and progression inMS. SCV loss was shown to be
directly aﬀected by inﬂammatory events (relapses), support-
ing at least a partial role of inﬂammation in driving neuro-
degeneration in MS. Finally, the study provides evidence of
a dissociation in the clinical consequences of SC volume loss
in RRMS vs SPMS. That said, SCV could be a useful endpoint
in clinical trials of therapeutic agents aimed at the de-
generative process in MS, a much wanted, unmet need.
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